Relevance and Efficiency of SecOnd Line Workup for Uveitis
NCT ID: NCT06102408
Last Updated: 2023-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2023-11-15
2023-12-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
NCT06273748
The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage
NCT05015335
Biologic Therapy in Pediatric JIA Uveitis
NCT05540743
Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study
NCT01717170
Cyclosporine A in the Treatment of Juvenile Idiopathic Arthritis (JIA) Associated Chronic Anterior Uveitis
NCT00404482
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with only one etiological workup
patients who underwent only one set of exams for etiological investigations of uveitis
second line investigations for uveitis etiological workup
Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
Patients without diagnostic modification subsequently to the second etiological workup
Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was not modified by the second line investigations.
second line investigations for uveitis etiological workup
Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
Patients with diagnostic modification subsequently to the second etiological workup
Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was modified by the second line investigations.
second line investigations for uveitis etiological workup
Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
second line investigations for uveitis etiological workup
Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least one etiological workup in our center
Exclusion Criteria
* diagnostic ophthalmologically obvious
* opposition to collection of data
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas MOULINET
Principal Investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Hwang DK, Chou YJ, Pu CY, Chou P. Epidemiology of uveitis among the Chinese population in Taiwan: a population-based study. Ophthalmology. 2012 Nov;119(11):2371-6. doi: 10.1016/j.ophtha.2012.05.026. Epub 2012 Jul 17.
Dandona L, Dandona R, John RK, McCarty CA, Rao GN. Population based assessment of uveitis in an urban population in southern India. Br J Ophthalmol. 2000 Jul;84(7):706-9. doi: 10.1136/bjo.84.7.706.
Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. doi: 10.1016/j.ajo.2005.03.057.
Smith JR, Rosenbaum JT. Management of uveitis: a rheumatologic perspective. Arthritis Rheum. 2002 Feb;46(2):309-18. doi: 10.1002/art.503. No abstract available.
Selmi C. Diagnosis and classification of autoimmune uveitis. Autoimmun Rev. 2014 Apr-May;13(4-5):591-4. doi: 10.1016/j.autrev.2014.01.006. Epub 2014 Jan 12.
de Parisot A, Jamilloux Y, Kodjikian L, Errera MH, Sedira N, Heron E, Perard L, Cornut PL, Schneider C, Riviere S, Olle P, Pugnet G, Cathebras P, Manoli P, Bodaghi B, Saadoun D, Baillif S, Tieulie N, Andre M, Chiambaretta F, Bonin N, Bielefeld P, Bron A, Mouriaux F, Bienvenu B, Amamra N, Guerre P, Decullier E, Seve P; ULISSE group. Evaluating the cost-consequence of a standardized strategy for the etiological diagnosis of uveitis (ULISSE study). PLoS One. 2020 Feb 14;15(2):e0228918. doi: 10.1371/journal.pone.0228918. eCollection 2020.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023PI190
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.